Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MigVax-101
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MigVax’s COVID-19 Vaccine Preclinical Trial Demonstrates Effectivity as a Booster
Details : In the trial, tests carried out on rats demonstrated that the MigVax-101 sub-unit oral vaccine, when administered in a boost format following an injected S1 protein, elicited markedly higher neutralizing antibody titers than rats receiving an oral placeb...
Product Name : MigVax-101
Product Type : Vaccine
Upfront Cash : Inapplicable
October 06, 2021
Lead Product(s) : MigVax-101
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Ourcrowd
Deal Size : $12.0 million
Deal Type : Financing
OurCrowd Leads $12 Million Investment Round in Israeli COVID-19 Vaccine Company MigVax
Details : Investment will accelerate path to clinical trials and bring Israel’s human coronavirus vaccine to market.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
April 22, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Ourcrowd
Deal Size : $12.0 million
Deal Type : Financing
Lead Product(s) : MigVax-101
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Ourcrowd
Deal Size : $100.0 million
Deal Type : Funding
OurCrowd Launches $100 Million Pandemic Innovation Fund
Details : First investments to include MigVax - Israeli contender to produce oral coronavirus vaccine, and Sight Diagnostics - rapid, accurate and safe blood test technology in use at hospitals with COVID-19 patients.
Product Name : MigVax-101
Product Type : Vaccine
Upfront Cash : Undisclosed
February 06, 2020
Lead Product(s) : MigVax-101
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Ourcrowd
Deal Size : $100.0 million
Deal Type : Funding